CSPHF Stock Financial Analysis - CStone Pharmaceuticals (OTCPK) Stock

Overview

CStone Pharmaceuticals, based in China, operates predominantly within the biopharmaceutical industry, focusing on the development and commercialization of innovative oncology medicines. Established with the aspiration to meet the urgent therapeutic needs in cancer treatments, CStone has quickly positioned itself as a significant player in precision oncology. The company's pipeline includes a range of products that are in various stages of clinical trials targeting multiple cancer types. Key projects include CS1001, an anti-PD-L1 antibody that has shown promising results in clinical studies. Additionally, CStone's strategic collaborations with global pharmaceutical companies aim to accelerate the development and global market access of its oncology therapies, further reinforcing its commitment to transforming cancer treatment paradigims.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for CStone Pharmaceuticals as of June 30, 2025 is 202.49 MM.
The operating income for CStone Pharmaceuticals as of June 30, 2025 is -368.71 MM.
The net income for CStone Pharmaceuticals as of June 30, 2025 is -377.09 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	202.49	-368.71	-377.09
2025-03-31	304.85	-232.03	-234.15
2024-12-31	407.20	-95.36	-91.21
2024-09-30	431.87	-212.11	-116.76
2024-06-30	456.53	-355.26	-142.31
2024-03-31	460.19	-480.41	-254.77
2023-12-31	463.84	-579.16	-367.23
2023-09-30	472.46	-683.26	-558.78
2023-06-30	481.07	-787.36	-750.34
2023-03-31	481.22	-849.75	-826.51
2022-12-31	481.36	-912.15	-902.68
2022-09-30	453.70	-1,184.07	-1,205.25
2022-06-30	426.03	-1,455.99	-1,507.82
2022-03-31	334.88	-1,642.72	-1,713.96
2021-12-31	243.72	-1,829.44	-1,920.10
2021-09-30	681.00	-1,470.07	-1,621.85
2021-06-30	1,118.28	-1,110.70	-1,323.61
2021-03-31	1,078.56	-1,101.32	-1,272.30
2020-12-31	1,038.83	-1,091.93	-1,221.00
2020-09-30	518.55	-1,506.40	-1,482.45
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30	-0.11	-0.11
2024-03-31	-0.20	-0.20
2023-12-31	-0.29	-0.29
2023-09-30	-0.45	-0.45
2023-06-30	-0.62	-0.62
2023-03-31	-0.69	-0.69
2022-12-31	-0.77	-0.77
2022-09-30	-1.03	-1.03
2022-06-30	-1.28	-1.29
2022-03-31	-1.46	-1.47
2021-12-31	-1.65	-1.65
2021-09-30	-1.42	-1.42
2021-06-30	-1.18	-1.19
2021-03-31	-1.18	-1.18
2020-12-31	-1.17	-1.17
2020-09-30	-1.45	-1.45
2020-06-30	-1.74	-1.74
2020-03-31	-2.04	-2.04

Cash Flow: Operations, Investing, Financing

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30
2025-03-31
2024-12-31	-343.18	-247.68	-12.90
2024-09-30	-389.16	-61.87	37.16
2024-06-30	-435.15	123.94	87.21
2024-03-31	-512.00	371.77	237.78
2023-12-31	-588.84	619.61	388.36
2023-09-30	-548.50	474.39	349.92
2023-06-30	-508.15	329.18	311.49
2023-03-31	-559.45	346.29	169.98
2022-12-31	-610.74	363.39	28.47
2022-09-30	-841.19	-158.35	42.11
2022-06-30	-1,071.64	-680.10	55.75
2022-03-31	-1,277.83	-753.33	74.03
2021-12-31	-1,484.02	-826.55	92.30
2021-09-30	-1,103.18	-279.86	749.67
2021-06-30	-722.33	266.82	1,407.03
2021-03-31	-615.20	723.78	1,398.23
2020-12-31	-508.07	1,180.73	1,389.43
2020-09-30	-920.32	1,259.75	694.46
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for CStone Pharmaceuticals as of June 30, 2025 is -0.06.
The roe for CStone Pharmaceuticals as of June 30, 2025 is -0.20.
The roic for CStone Pharmaceuticals as of June 30, 2025 is -0.13.
The croic for CStone Pharmaceuticals as of June 30, 2025 is -0.85.
The ocroic for CStone Pharmaceuticals as of June 30, 2025 is -0.48.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.06	-0.20	-0.13	-0.85	-0.48
2025-03-31	-0.06	-0.20	-0.13	0.00	0.00
2024-12-31	-0.09	-0.31	-0.18	-0.28	-0.54
2024-09-30	-0.09	-0.31	-0.18	-0.28	-0.54
2024-06-30		-0.42
2024-03-31		-0.82
2023-12-31			-1.11	0.61
2023-09-30			-1.15	0.27
2023-06-30		-0.79
2023-03-31		-0.87
2022-12-31
2022-09-30		0.00
2022-06-30		0.00	0.00
2022-03-31		0.00
2021-12-31		0.00
2021-09-30	0.00	0.00
2021-06-30	-0.57		-0.54	0.29	-0.30
2021-03-31	-0.55	-0.65	-0.52	0.54	-0.25
2020-12-31	-0.41	-0.49	-0.40	0.62	-0.17
2020-09-30	-0.50	-0.60	-0.49	0.32	-0.30
2020-06-30	-0.51	-0.52	-0.88	0.04	-0.67
2020-03-31	-0.59	-0.61	-1.02	0.13	-0.61

Gross Margins

The gross margin for CStone Pharmaceuticals as of June 30, 2025 is 0.59.
The net margin for CStone Pharmaceuticals as of June 30, 2025 is -0.22.
The operating margin for CStone Pharmaceuticals as of June 30, 2025 is -0.23.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.59	-0.22	-0.23
2025-03-31	0.59	-0.22	-0.23
2024-12-31	0.71	-0.31	-0.78
2024-09-30	0.71	-0.31	-0.78
2024-06-30
2024-03-31
2023-12-31
2023-09-30		-1.56	-1.64
2023-06-30		-1.56	-1.64
2023-03-31		-1.72	-1.77
2022-12-31
2022-09-30
2022-06-30		0.00	0.00
2022-03-31
2021-12-31
2021-09-30
2021-06-30	0.76	-1.18	-0.99
2021-03-31	0.76	-1.18	-1.02
2020-12-31	0.77	-1.18	-1.05
2020-09-30	0.77	-2.88	-2.94
2020-06-30	1.00	-277.16	-304.01
2020-03-31	1.00	-644.05	-580.09

DE:PH4	€1.35
HK:2616	HK$12.33